for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sun Pharmaceutical Industries Limited

SUN.NS

Latest Trade

838.50INR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

550.40

 - 

871.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
838.50
Open
--
Volume
--
3M AVG Volume
80.97
Today's High
--
Today's Low
--
52 Week High
871.00
52 Week Low
550.40
Shares Out (MIL)
2,399.33
Market Cap (MIL)
2,031,517.00
Forward P/E
27.97
Dividend (Yield %)
0.89

Next Event

Q3 2022 Sun Pharmaceutical Industries Ltd Earnings Release

Latest Developments

More

Sun Pharma Says Its Unit DUSA Pharmaceuticals Reached Settlement With Biofrontera

Sun Pharma Says Unit Recalled 69,336 Blister Packs Of Loratadine From U.S. Market

Sun Pharma's U.S.-Based Units Sign Settlement Agreements In Generic Pharmaceuticals Pricing Antitrust Litigation

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.

Industry

Biotechnology & Drugs

Contact Info

Sun House, CTS No. 201 B/1,, Western Exp

400063

India

+91.22.43244324

http://www.sunpharma.com/

Executive Leadership

Israel Makov

Non-Executive Chairman of the Board

C. S. Muralidharan

Chief Financial Officer

Uday Baldota

Chief Executive Officer - Taro Pharmaceutical Industries Limited

Abhay Gandhi

Chief Executive Officer, North America

Kirti Ganorkar

Chief Executive Officer - India Business

Key Stats

1.75 mean rating - 36 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2019

290.7K

2020

328.4K

2021

335.0K

2022(E)

382.5K
EPS (INR)

2019

16.060

2020

16.780

2021

30.040

2022(E)

30.316
Price To Earnings (TTM)
32.64
Price To Sales (TTM)
5.53
Price To Book (MRQ)
4.10
Price To Cash Flow (TTM)
24.24
Total Debt To Equity (MRQ)
10.61
LT Debt To Equity (MRQ)
1.31
Return on Investment (TTM)
12.59
Return on Equity (TTM)
9.16

Latest News

Latest News

Indian shares slip as Sun Pharma drags ahead of earnings

Indian shares reversed course to fall slightly on Tuesday as pharmaceutical stocks lost their footing on the back of a slide in heavyweight Sun Pharma ahead of its quarterly earnings results later in the day.

Sensex, Nifty end higher as stronger dollar lifts IT stocks

Indian shares ended with gains on Wednesday as a tightening U.S. presidential election boosted the dollar and helped buoy domestic IT shares, with Reliance Industries and pharma stocks also providing support.

Sun Pharma latest to sell COVID-19 drug favipiravir in India

India's Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world's third worst-hit nation.

BRIEF-Sun Pharma Unit Gets Japan's Nod For ILUMYA To Treat Plaque Psoriasis

* UNIT GETS JAPAN MHLW APPROVAL OF ILUMYA FOR TREATMENT OF PLAQUE PSORIASIS Source text for Eikon: Further company coverage:

BRIEF-Sun Pharma, Hikma Sign Exclusive Licensing Deal For Ilumya For MENA Region

* SUN PHARMA AND HIKMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR ILUMYA FOR MIDDLE EAST & NORTH AFRICA REGIONS

Sun Pharma testing plant-based drug as potential COVID-19 treatment

Indian drugmaker Sun Pharmaceutical Industries Ltd said on Friday it was testing a plant-derived drug, AQCH, for the potential treatment of COVID-19 as part of a mid-stage trial, with results expected by October.

BRIEF-Sun Pharma Gets Indian Regulatory Nod For Nafamostat Study In COVID-19 Patients

* RECEIVES APPROVAL FROM DCGI TO INITIATE CLINICAL TRIAL WITH NAFAMOSTAT IN COVID-19 PATIENTS Source text for Eikon: Further company coverage:

Sun Pharma to test pancreatitis drug in COVID-19 patients in India

Drugmaker Sun Pharmaceutical Industries Ltd said on Friday it has received Indian regulatory approval to start clinical trials of a pancreatitis drug in COVID-19 patients.

India's Sun Pharma to conduct clinical trial of pancreatitis drug in COVID-19 patients

Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.

BRIEF-Sun Pharmaceutical Industries Says Co, SPARC Enter Worldwide License Agreement For SCD-044

* SUN PHARMACEUTICAL INDUSTRIES LTD - SPARC AND SUN PHARMA ENTER INTO A WORLDWIDE LICENSE AGREEMENT FOR SCD-044

BRIEF-India's Sun Pharmaceutical Industries March Qtr Consol Net PAT Falls

* MARCH-QUARTER CONSOL NET PAT 4 BILLION RUPEES VERSUS PROFIT OF 6.36 BILLION RUPEES YEAR AGO

BRIEF-Sun Pharmaceutical Says Received Communication From USFDA

* SUN PHARMACEUTICAL SAYS RECEIVED COMMUNICATION FROM USFDA INDICATING THAT HALOL FACILITY HAS BEEN CLASSIFIED AS “OFFICIAL ACTION INDICATED”

Sun Pharma's U.S. unit donates malaria drug in coronavirus fight

Sun Pharmaceutical Industries Ltd's U.S. subsidiary said on Friday it had donated 2.5 million hydroxychloroquine sulfate tablets as a potential treatment for the rapidly spreading coronavirus.

Sun Pharma's U.S. unit donates hydroxychloroquine sulfate tablets in fight against coronavirus

A subsidiary of India's Sun Pharmaceutical Industries Ltd said on Friday it had donated 2.5 million hydroxychloroquine sulfate tablets in the United States as a potential treatment for coronavirus.

BRIEF-India's Sun Pharma To Buy Back Shares For Up To 17 Bln Rupees

* TO BUY-BACK SHARES AT A MAXIMUM PRICE OF 425 RUPEES PER SHARE

BRIEF-Sun Pharma To Consider Share Buyback On March 17 - Statement

* TO CONSIDER SHARE BUYBACK ON MARCH 17 - STATEMENT Further company coverage: (Reporting by Aftab Ahmed)

BRIEF-India's Sun Pharma Says Does Not Source API Of Pindolol From China

* SHORTAGE OF PINDOLOL IS DUE TO UNAVAILABILITY OF API SUPPLIES; CO DOESN’T SOURCE API OF PINDOLOL FROM CHINA - SUN PHARMA STATEMENT Further company coverage:

UPDATE 2-India's Sun Pharma says hypertension drug in shortage in US

Indian drugmaker Sun Pharmaceutical Industries Ltd reported a shortage of its generic version of hypertension drug pindolol in the United States due to a lack of pharmaceutical ingredients, but said the shortfall did not stem from China.

India's Sun Pharma flags hypertension drug shortage due to supply constraint

Indian drugmaker Sun Pharmaceutical Industries Ltd said on Monday there was a shortage of its generic version of hypertension drug pindolol due to unavailability of supply of the drug's ingredients.

BRIEF-India's Sun Pharma Launches RIOMET ER Oral Suspension In The U.S.

* LABEL FOR RIOMET ER CARRIES BOXED WARNING ABOUT RISK OF LACTIC ACIDOSIS WITH EXCESSIVE ALCOHOL INTAKE Source text: (http://bit.ly/2wGSrZ0) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up